CalciMedica Secures $49M Financing to Advance PH Program
LA JOLLA, Calif., June 24, 2026 CalciMedica, Inc. (Nasdaq: CALC) announced a private placement financing of up to approximately...
AI drug discovery AI healthcare artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biopharmaceuticals Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine targeted therapy
LA JOLLA, Calif., June 24, 2026 CalciMedica, Inc. (Nasdaq: CALC) announced a private placement financing of up to approximately...
LA JOLLA, Calif., June 24, 2026 CalciMedica, Inc. announced that the U.S. Food and Drug Administration (FDA) has completed...
